Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer
This study has been completed.
Study NCT00176644   Information provided by University of Medicine and Dentistry New Jersey

First Received on September 13, 2005.   Last Updated on December 10, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Prostate Cancer
Additional conditions recognized in this trial
Prostatic Neoplasms
More general conditions related to this trial
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Interventions listed in this trial
Transdermal Estradiol
Additional drug interventions recognized in this trial
Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Estradiol valerate
Hormones
Polyestradiol phosphate
More general drug interventions related to this trial
Contraceptive Agents
Contraceptive Agents, Female
Estrogens
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses
Sponsors listed in this trial
University of Medicine and Dentistry New Jersey


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services